Details for Patent: 10,323,001

« Back to Dashboard

Which drugs does patent 10,323,001 protect, and when does it expire?

Patent 10,323,001 protects KLISYRI and is included in one NDA.

This patent has thirty-four patent family members in thirteen countries.

Summary for Patent: 10,323,001

Title:	Compositions for modulating a kinase cascade and methods of use thereof
Abstract:	The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present invention also provides a novel polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure.
Inventor(s):	David G. Hangauer, Jr., Debasis Patra, Jeremy A. Cody, Grant J. Palmer, Paul K. Isbester, Jonathon Salsbury
Assignee:	Atnx Spv LLC
Application Number:	US15/387,322
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,323,001
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 10,323,001

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Almirall	KLISYRI	tirbanibulin	OINTMENT;TOPICAL	213189-001	Dec 14, 2020		RX	Yes	Yes	10,323,001		Y

International Family Members for US Patent 10,323,001

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007340350
Australia	2008254500
Canada	2673974
Canada	2686267